Pharmaceuticals, Biotechnology and Life Sciences
LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic…
Designation based on phase 2 DESTINY-Lung01 This is the third Breakthrough Therapy Designation for ENHERTU, highlighting its potential to treat…
In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…
In CheckMate -227 Part 1a, Opdivo + Yervoy showed superior and durable long-term overall survival versus chemotherapy1,2,3 Fifth indication for…
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR)…
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates…
Companies selling personal protective equipment like face masks and gloves seem to be having a hard time getting their products to their target audience, no thanks to the practices of online platforms such as search engines, online stores, and social media networking sites.
Pomalyst is the only oral and first new treatment option for Kaposi sarcoma in more than 20 years1,2 Approval based…
RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models CAMBRIDGE,…